| Effect of urate-elevating inosine on early Parkinson disease progression: the SURE-PD3 randomized clinical trial B Bluett, DM Togasaki, D Mihaila, M Evatt, M Rezak, S Jain, ... Jama 326 (10), 926-939, 2021 | 83 | 2021 |
| Prospective home-use study on non-invasive neuromodulation therapy for essential tremor SH Isaacson, E Peckham, W Tse, O Waln, C Way, MT Petrossian, ... Tremor and Other Hyperkinetic Movements 10, 2020 | 49 | 2020 |
| Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial MJ Soileau, J Aldred, K Budur, N Fisseha, VSC Fung, A Jeong, TE Kimber, ... The Lancet Neurology 21 (12), 1099-1109, 2022 | 42 | 2022 |
| Caregiver burden in patients with Parkinson disease undergoing deep brain stimulation: an exploratory analysis MJ Soileau, C Persad, J Taylor, PG Patil, KL Chou Journal of Parkinson's disease 4 (3), 517-521, 2014 | 41 | 2014 |
| Intracranial atherosclerosis is associated with progression of neurological deficit in subcortical stroke H Hallevi, OY Chernyshev, R El Khoury, MJ Soileau, KC Walker, ... Cerebrovascular Diseases 33 (1), 64-68, 2012 | 36 | 2012 |
| 24-hour levodopa-carbidopa intestinal gel: clinical experience and practical recommendations S Thakkar, VSC Fung, A Merola, M Rollins, MJ Soileau, N Kovács CNS drugs 35, 137-149, 2021 | 24 | 2021 |
| Does the 5–2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5–2-1-positive patients in 7 countries IA Malaty, P Martinez-Martin, KR Chaudhuri, P Odin, M Skorvanek, ... BMC neurology 22 (1), 35, 2022 | 15 | 2022 |
| Factor structure of the Montreal Cognitive Assessment items in a sample with early Parkinson's disease JF Benge, S Balsis, T Madeka, C Uhlman, C Lantrip, MJ Soileau Parkinsonism & related disorders 41, 104-108, 2017 | 12 | 2017 |
| Comparative Effectiveness of Carbidopa–Levodopa Enteral Suspension and Deep Brain Stimulation on Parkinson’s Disease-Related Pill Burden Reduction in Advanced Parkinson’s … MJ Soileau, F Pagan, A Fasano, R Rodriguez-Cruz, L Wang, ... Neurology and therapy 11 (2), 851-861, 2022 | 7 | 2022 |
| Placement of the AbbVie PEG-J tube for the treatment of Parkinson's disease in the interventional radiology suite ML Montgomery, NK Miner, MJ Soileau, DK McDonald Baylor University Medical Center Proceedings 29 (4), 420-422, 2016 | 7 | 2016 |
| Psychometric properties of clinical indicators for identification and management of advanced Parkinson’s disease: real-world evidence from G7 countries A Antonini, R Pahwa, P Odin, T Henriksen, MJ Soileau, R Rodriguez-Cruz, ... Neurology and therapy 11 (1), 303-318, 2022 | 6 | 2022 |
| The Everyday Cognition scale in Parkinson's disease RA Cooper, J Benge, C Lantrip, MJ Soileau Baylor University Medical Center Proceedings 30 (3), 265-267, 2017 | 6 | 2017 |
| Pathophysiology, Genetics, Clinical Manifestations, and Course including Diagnosis and Differential Diagnosis MJ Soileau, KL Chou Neurobiology of Disease, 2016 | 2 | 2016 |
| Efficacy and safety of foslevodopa/foscarbidopa continuous subcutaneous infusion administered as monotherapy in patients with Parkinson’s disease J Aldred, T Henriksen, M Bouchard, JC Martínez-Castrillo, MJ Soileau, ... Parkinsonism & Related Disorders 122, 2024 | 1 | 2024 |
| Continuous subcutaneous Foslevodopa/Foscarbidopa infusion for the treatment of motor fluctuations in Parkinson’s Disease: Considerations for initiation and maintenance VSC Fung, J Aldred, MP Arroyo, F Bergquist, AJW Boon, M Bouchard, ... Clinical Parkinsonism & Related Disorders, 100239, 2024 | 1 | 2024 |
| Comparative Effectiveness of Carbidopa/Levodopa Enteral Suspension and Deep Brain Stimulation on Pill Burden Reduction in Medicare Fee-for-Service Patients with Advanced … MJ Soileau, FL Pagan, A Fasano, R Rodriguez-Cruz, CH Yan, NR Gupta, ... Neurology and Therapy 12 (2), 459-478, 2023 | 1 | 2023 |
| Rapid onset of good ON time and improvement in motor-state stability in aPD patients after treatment with continuous subcutaneous foslevodopa/foscarbidopa R Pahwa, M Soileau, D Standaert, V Fung, T Kimber, I Malaty, A Merola, ... Movement disorders 37, S346-S346, 2022 | 1 | 2022 |
| Real-world characteristics and treatment persistence in patients initiating CLES: results from a cohort of 1290 patients in USA F Pagan, R Rodriguez-Cruz, M Soileau, A Alobaidi, P Kandukuri, O Hayes, ... NEUROLOGY 96 (15), 2021 | 1 | 2021 |
| Pill burden reduction in patients with advanced Parkinson's disease: comparative effectiveness of carbidopa/levodopa enteral suspension and deep brain stimulation M Soileau, F Pagan, A Fasano, R Rodriguez-Cruz, M Oh, P Kandukuri, ... MOVEMENT DISORDERS 35, S483-S484, 2020 | 1 | 2020 |
| Neurology Self-Assessment: A Companion to Bradley's Neurology in Clinical Practice E-Book: Neurology Self-Assessment: A Companion to Bradley's Neurology in Clinical Practice E-Book JT Jordan, DR Mayans, MJ Soileau Elsevier Health Sciences, 2016 | 1 | 2016 |
